---
title: "Insilico Medicine Reports 40% Response Rate at 130 mg for ISM6331 in Phase 1 Mesothelioma Trial"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/303086760.md"
description: "Insilico Medicine reported a 40% response rate for its AI-designed drug ISM6331 at 130 mg in a Phase 1 mesothelioma trial. Presented at ESMO 2026, results showed tumor shrinkage and disease control with no dose-limiting toxicities. The company plans to finalize dose selection before potentially launching a Phase 2a randomized study."
datetime: "2026-10-26T13:02:14.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/303086760.md)
  - [en](https://longbridge.com/en/news/303086760.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/303086760.md)
generator: "portal-rs"
---

# Insilico Medicine Reports 40% Response Rate at 130 mg for ISM6331 in Phase 1 Mesothelioma Trial

-   Insilico Medicine reported encouraging Phase 1 results for AI-designed cancer drug ISM6331 in heavily pretreated mesothelioma. \* Results presented at ESMO 2026 in Madrid showed tumor shrinkage and disease control, with some responses ongoing at the data cutoff. \* No dose-limiting toxicities were reported; treatment-related side effects were mostly mild or moderate, with none leading to discontinuation. \* The company plans to complete dose selection before potentially initiating a Phase 2a randomized dose-optimization study in mesothelioma. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Insilico Medicine Cayman Topco published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610260900PR\_NEWS\_USPR\_\_\_\_\_CN80710) on October 26, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [03696.HK](https://longbridge.com/en/quote/03696.HK.md)

## Related News & Research

- [Insilico Medicine Subsidiary Partners With Luoxin Pharmaceuticals on AI-Powered Drug Discovery](https://longbridge.com/en/news/305433887.md)
- [Chainfir Capital says AI drug deal headlines mask reliance on uncertain milestone payments](https://longbridge.com/en/news/302495363.md)
- [INSILICO Plans Share Buyback of Up to HKD500M](https://longbridge.com/en/news/303654455.md)
- [InSilico Medicine Hits Early AI Drug Discovery Milestone in Servier Collaboration](https://longbridge.com/en/news/302341377.md)
- [Insilica und ProtoQSAR integrieren ProtoPRED® in ToxIndex, um die Bewertung der Chemikaliensicherheit voranzutreiben](https://longbridge.com/en/news/302778058.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**